OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ:TBIO), today announced that it is launching a new pilot clinical study of its Multiplexed ICE COLD-PCR™ (MX-ICP) liquid biopsy technology. Four leading global biopharmaceutical firms have joined the pilot program, which was initiated with an undisclosed market-leading oncology company earlier this year. The primary aim of the study is to validate the accuracy and utility of using MX-ICP-based liquid biopsies, which analyze circulating tumor DNA in the blood to guide and monitor cancer clinical trials. The study will include a variety of cancers and several different sequencing platforms.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
